Investor Lupton argues Hims & Hers and NURS.V stand to benefit most if regulators move peptides back to category 1. This is his own view as an investor, not a regulatory decision.
Recap by typeshit. Post by Jonah Lupton on X.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Adding an experimental hormone mimic to tirzepatide pushed body mass reduction as high as 23.3% in a Lilly clinical trial, per NewsBytes.
Novo also presented liver fat data from STEP-UP and an Ozempic vs Mounjaro heart risk analysis, and paid $300 million upfront for Hengrui's HRS-1596.
Loading…